Enterprise Value
523.7M
Cash
320.1M
Avg Qtr Burn
-54.52M
Short % of Float
10.82%
Insider Ownership
7.91%
Institutional Own.
92.98%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ABBV-RGX-314 (Subretinal Delivery) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Phase 2 Data readout | |
ABBV-RGX-314 (Suprachoroidal Delivery) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Phase 2 Data readout | |
ABBV-RGX-314 (Suprachoroidal Delivery) Details Diabetes, Eye disease , Diabetic retinopathy | Phase 2 Data readout | |
RGX-121 Details Rare diseases, Mucopolysaccharidosis type II, Pulmonary arterial hypertension, Lung disease, Genetic disorder, Rare genetic disease, Mucopolysaccharidoses | Phase 1/2 Data readout | |
RGX-381 Details Central nervous system illness | Phase 1/2 Data readout | |
RGX-202 Details Rare diseases, Genetic disorder, Rare genetic disease, Duchenne muscular dystrophy | Phase 1/2 Data readout | |
RGX-111 Details Rare diseases, Genetic disorder, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis Type 1 | Phase 1/2 Update | |
RGX-181 Details Central nervous system illness, Batten Disease | Phase 1 Data readout |